13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D/A Filed 2026-09-04 Event 2024-05-15 SEC 0001193125-26-383775 →

Lantheus Holdings, Inc. Perspective Therapeutics, Inc. CATX

Stake: 10.00% Shares: 11,440,513 CUSIP: 46489V302 Class: Common Stock, $0.001 par value

Item 4 — Purpose of Transaction

Item 4 of the Original Statement is hereby amended and supplemented to add the following: As of the date of this Amendment No. 2, the Reporting Persons are authorized to sell their shares of Common Stock subject to certain market conditions from time to time, in each case whether through privately negotiated transactions, open market transactions, block trades, registered offerings, underwritten transactions, accelerated transactions, derivative transactions, collars, prepaid forward transactions, swaps, exchange transactions, brokerage transactions or otherwise.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
3 13D/G filings on this issuer
2 other filings besides this one
Filer Track Record
3 filings by this filer
2 other filings in the data moat
Short Interest · settle 2026-08-14
DTC 18.22
23,038,136 shares short · -1.9% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $864K
Point72 Asset Mgmt

Other 13D/G Filings on Perspective Therapeutics, Inc.

FiledFormFilerStakeShares
2026-07-20 SCHEDULE 13G MILLENNIUM MANAGEMENT LLC view →
2026-06-30 SCHEDULE 13G MILLENNIUM MANAGEMENT LLC view →

Other Filings by Lantheus Holdings, Inc.

FiledFormIssuerStakeShares
2026-09-04 SCHEDULE 13D Radiopharm Theranostics Limited 20.90% 792,958,513 view →
2020-06-23 SC PROGENICS PHARMACEUTICALS INC view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →